¿øÀº¼ö
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ¿ì¿ï,ºÒ¾È,½ºÆ®·¹½º,Á¾¾çÁ¤½ÅÀÇÇÐ
Á÷
ˤ
: Á¶±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
30
ÇØ¿Ü
Influence of BclI C/G (rs41423247) on hippocampal shape and white matter integrity of the parahippocampal cingulum in major depressive disorder.(2016)
29
ÇØ¿Ü
Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants(2015)
28
ÇØ¿Ü
Imaging genetics studies on monoaminergic genes in major depressive disorder.(2016)
27
ÇØ¿Ü
The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events.(2015)
26
ÇØ¿Ü
Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine.(2014)
25
ÇØ¿Ü
Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition.(2014)
24
ÇØ¿Ü
Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.(2012)
23
ÇØ¿Ü
Understanding Depression Volume 1. Biomedical and Neurobiological Background(2018)
22
ÇØ¿Ü
Panic Disorder: Assessment, Management and Research Insights(2018)
21
ÇØ¿Ü
Whole-exome sequencing identifies variants associated with structural MRI markers in patients with bipolar disorders(2019)
1
2
3
4
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729